Vildagliptin - a new dipeptidylpeptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

The course of type 2 diabetes mellitus (type 2 DM) is characterized by progressive decline in beta-cell function, regardless of ongoing therapy and body mass. Reduced ability of insulin secretion by beta-cells along with demand for it on the background of insulinoresistance is the characteristics of type 2 DM. This circumstance dictates the need for creation of new drugs that not only eliminate specific metabolic disorders, but also maintain the safety of beta-cells functional activity. The data for the use of dipeptidilpeptidaze-4 (DPP-4) inhibitor - vildagliptin (Galvus 50 mg) and combined drug (GalvusMet; vildagliptin 50 mg + metformin 500, 850 or 1000 mg) for therapy of type 2 diabetes mellitus are presented. Studies results have shown that both drugs improve parameters of carbohydrate metabolism, blood pressure, not cause increase in body weight, and characterized by good tolerability. Identified characteristics of vildagliptin as an inhibitor of DPP-4 offer new opportunities to improve the effectiveness of treatment of type 2 diabetes mellitus.

insulin-independent diabetes, dypeptydilpepetidase-IV inhibitor (DPP-IV), vildagliptin, vildagliptin + metformin